Timothy E. Morris Email & Phone Number

Austin, Tx, Us

Aacolade Pharma LLC is a boutique biotech advisory firm serving clients worldwide. The firm is led by Timothy E. Morris, a retired biotech CFO. Mr. Morris has over 25 years of experience as a public company CFO. He has raised over $2.5 billion and completed over 100 corporate transaction. Mr. Morris and his team of experts provide advisory services including assistance with fundraising, reverse mergers, out licensing, divestitures, spinoffs, product acquisitions, debt financings, royalty monetization, investor relations, public relations, reduction in force and general corporate advise. Mr. Morris is a Financial Expert under NASDAQ and SEC rules and provides his services as an Audit Committee member or chairmen and a member of the Board of Directors. To ensure personal attention and high touch engagement, Aacolade Pharma limits the number of active projects. If you interested in engaging Aacolade Pharma please send project details including scope and timelines to tmorris@aacolade.com +1-650-400-6874.

Aquestive Therapeutics, Inc. (Nasdaq: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standard of care and provide transformative products to improve their lives. They are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut syndrome. Their licensees market their products in the U.S. and around the world. The company collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best in class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage pipeline focused on treating diseases of the central nervous system and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.

Bruxelles, Brussels, Be

Univercells is a global life sciences company with the mission of making biologics accessible to all. Using their combined expertise in scaling, production, and bioprocessing, Univercells finds new and sustainable ways to widen access to life-changing drugs. The affiliate companies deploy innovations in infrastructure, drug substance manufacturing, equipment manufacturing, equipment design, training, and on-the-ground health services to drive down costs, shrink manufacturing footprints and meet the needs of the entire health value chain. Univercells is supported by regional and national investors, as well as international investors active in vaccines and healthcare, such as the Bill and Melinda Gates Foundation, the European Investment Bank and Global Health Investment Fund.

Châtillon, France, Fr

DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, DBV is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV Technologies is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and North American operations in Summit, NJ

Minneapolis, Mn, Us

Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. The Company was founded in 1988 and is engaged in developing and commercializing products to enhance human health and wellbeing. Humanetics entered the field of radiation modulators in 2003, through a cooperative research program with the Armed Forces Radiobiology Research Institute (AFRRI). AFRRI's mission is the discovery and early development of drugs that can protect warfighters from the harmful effects of radiation. Humanetics began working with AFRRI to test an array of drug candidates using their highly developed capabilities. From this program, BIO 300 emerged as a lead candidate and the underlying technology was in-licensed from the Department of Defense to Humanetics. In the ensuing years, the Company has progressed this program into clinical stage with a primary focus on improving the treatment outcomes for patients receiving radiation treatment of solid tumors. Humanetics has three open INDs for BIO 300. They have active clinical programs focused on medical countermeasures, solid tumor radiotherapy and in COVID-19.

South Yarra, Vic, Au

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Humanigen is developing lenzilumab as a treatment for CMML and acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation. The clinical efforts in COVID-19 were not statistically significant and the company has deprioritized the development of Lenz for COVID.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection as well as the serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The company’s immediate focus is to prevent or minimize the cytokine storm that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection and also in combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered®anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, to evaluate the sequential use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma is currently enrolling. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.

San Carlos, California, Us

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. After infusion, TIL reach tumor tissue, where they attack tumor cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and is currently conducting a pivotal study in patients with advanced cervical cancer. In addition, the company’s TIL therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment. For more information, please visit www.iovance.com.

San Mateo, California, Us

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Mr. Morris was responsible for managing the company's finance operations, corporate development, information systems, commercial strategy, joint steering committee and investor relations functions. The Company's late-stage pipeline includes DSUVIAS (sufentanil sublingual tablet, 30 mcg), designed for the treatment of moderate-to-severe acute pain in medically supervised settings. AcelRx has filed the NDA for DSUVIA and the MAA in 2017. AcelRx intends to commercialize DSUVIA through its own sales force initially for use in the Emergency Department. AcelRx's second product is Zalviso® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital. Zalviso delivers 15 mcg sufentanil sublingually through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. Zalviso is approved in the EU and is in phase 3 in the U.S. Grunenthal Group holds the rights for Zalviso in Europe and has launched Zalviso in 9 EU countries.

PAION Inc. is a wholly owned subsidiary of PAION AG. PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The company has a track record of developing hospital-based treatments for which there is substantial unmet medical need. PAION’s strategy is to participate in the commercialization of Remimazolam and extend its business with a focus on anesthesia/critical care products. PAION Inc. is focused on the development of Remimazolam for procedural sedation for the US market and is currently in phase 3 clinical trials.

Campbell, California, Us

Chief Financial Officer, Senior Vice President Global Corporate Development and Finance - VIVUS Inc. (NASDAQ: VVUS) is a biopharmaceutical company focused on the development and commercialization of therapies to treat obesity and restore sexual health. VIVUS’ lead product is Qsymia, a proprietary oral treatment for obesity, was approved in July 2012 and launched in September 2012. Our second product, STENDRA, a next generation PDE5i, was approved in April 2102. In my nine years at VIVUS we have successfully received FDA approval for three products and EU approval for one of those products. The company has tripled in size in the last year and we are now a fully integrated commercial pharmaceutical company. During my rein as CFO the market cap has increased five times to $1 billion. Current responsibilities include finance, corporate development, IT, human resources, legal, and investor relations. I have raised $750 million through 9 separate raises, including a recent $250 million convertible offering and a $110 royalty financing. I have designed and implemented an effective investor relations program resulting in several new sell side analyst reports, and an increase in the institutional shareholders base. I completed divestiture of the manufacturing facility and legacy product line. I reorganized finance department and international corporate structure, implemented full Sarbanes Oxley controls and systems, and selected independent auditors and corporate counsel. In the 2012 I led effort to recruit and hire over 100 new employees to install the commercial infrastructure. In 2012 I assumed the Global Corporate Development activities and am lead our efforts to partner our products worldwide. I recently completed partnering agreement for the US rights to STENDRA worth over $300 million to VIVUS and a separate agreement for ROW rights worth over $60 million.

Hayward, Ca, Us

Member of the Office of the President, Chief Financial Officer and Sr. Vice President Finance, Manufacturing & Administration - Questcor Pharmaceuticals Inc. (AMEX: QSC now NASDAQ: QCOR) is a specialty pharmaceutical company focused on the development, acquisition and marketing of pharmaceutical products. The Company historically marketed five products in the US. I was promoted to the Office of the President in August 2004 to assume leadership responsibilities of the entire organization upon departure of CEO. Additional responsibilities include finance, manufacturing, regulatory, quality assurance, mergers and acquisitions, legal, corporate governance, investor relations, information systems, facilities, human resources, accounting and administration. Accomplishments include:• Raised $24 million in private equity and debt over three years to finance acquisitions and growth• Built company to obtain revenues in excess of $16M and EBITDA positive in 3 years• Sourced, negotiated and closed acquisition of FDA approved product• Established new disclosure and financial reporting systems to ensure compliance with Sarbanes Act• Established quality relationships with specialty pharmaceutical/healthcare analysts and bankers• Recruited and built current finance, contract manufacturing, regulatory and quality team• Company spokesman at industry conferences and for analysts, investors and the media• Completed five-year strategic plan

Sydney, Nsw, Au

Chief Financial Officer - InterPro was a provider of travel & expense reporting automation services to large corporations worldwide. Its offerings include software, consulting and business process outsourcing services. The Company had over 100 people in two divisions with combined revenue run rate of over $12 million with an annualized operating budget of $20 million. Responsible for all financial, legal and administrative aspects of the Company. The travel & expense reporting division was rolled back into the parent corporation in the fall of 2001.

Vice President Finance & Administration and Chief Financial Officer - RiboGene, Inc. (Amex: RBO) a publicly held biopharmaceutical company merged with Cypros Pharmaceuticals to become Questcor Pharmaceuticals (Amex: QSC). The Company was pursuing the discovery and development of human pharmaceuticals. Responsibilities and duties include managing a staff of 6 in finance, information systems, facilities, health & safety, human resources, intellectual property, corporate communications, legal, investor and public relations and administration. • Completed IPO for RiboGene in May 1998 (AMEX:RBO), One of nine biotech IPO's in 1998• Raised over $50 million (private $30 million from VC's, public $20 million)• Second in command behind Chief Executive Officer• Provide business development, financial and negotiation support for all strategic alliances• Company spokesman at industry conferences and for analysts, investors and the media• Built operational infrastructure to support a 100% growth in headcount• Responsible for construction of and relocation to a new state-of-the-art facility

London, Gb